title: [Development of acute coronary syndrome in three patients with essential thrombocythemia or polycythemia vera].
abstract: Little is known about the management of coronary thrombosis in myeloproliferative disease. The occurrence of myocardial infarction in myeloproliferative disease is mostly attributed to coronary thrombosis due to hyperviscosity and thrombocytosis. We presented three cases of acute myocardial infarction associated with polycythemia vera in one patient (male, age 33 years) and essential thrombocytosis in two patients (male, ages 36 and 46 years). None of the patients had diabetes mellitus, hypertension, hyperlipidemia, or a positive family history. One patient with early presentation received thrombolytic therapy, and all the patients were treated with aspirin, beta-blocker, angiotensin 2 receptor blocker, statin, low-molecular-weight heparin, parenteral nitrate, and clopidogrel for acute coronary syndrome, and hydroxyurea for essential thrombocytosis. Control angiographies showed patent coronary arteries in all the cases.
authors.affiliation: Ankara Numune Eğitim ve Araştirma Hastanesi Kardiyoloji Kliniği, Ankara. meltemtekin@gmail.com
authors.forename: Meltem
authors.initials: M
authors.lastname: Tekin
authors.forename: Serkan
authors.initials: S
authors.lastname: Gökaslan
authors.forename: Erdem
authors.initials: E
authors.lastname: Diker
authors.forename: Sinan
authors.initials: S
authors.lastname: Aydoğdu
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage; D000986:Antisickling Agents / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage; D017023:Coronary Angiography; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis* / Q000000981:diagnostic imaging; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011087:Polycythemia Vera / Q000150:complications*; D013922:Thrombocytosis / Q000150:complications*; D015912:Thrombolytic Therapy
chemical_list: D000925:Anticoagulants; D000986:Antisickling Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin; D006918:Hydroxyurea